NCT01175564View on ClinicalTrials.gov

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Healthy
Interventions
DRUG

TC-5214

Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet

DRUG

Placebo

Placebo tablet, single dose and 6 days repeated dose

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY